TFK-1 Xenograft Model Service for Biliary Tract Cancer

The TFK-1 Xenograft Model Service for Biliary Tract Cancer provides a robust, clinically relevant preclinical platform for evaluating novel therapeutic candidates against extrahepatic cholangiocarcinoma, one of the most aggressive and treatment-resistant malignancies of the hepatobiliary system. At Alfa Cytology, we specialize in delivering high-fidelity, preclinical-grade TFK-1 xenograft models engineered to accelerate your drug discovery pipeline---from target validation and lead optimization to pharmacodynamic profiling and combination regimen assessment---ensuring reproducible, publication-ready data that supports informed go/no-go decisions.

Overview of TFK-1 Xenograft Model for Biliary Tract Cancer

The TFK-1 cell line was originally established in 1995 from a surgically resected extrahepatic bile duct carcinoma specimen, histologically characterized as partly papillary adenocarcinoma and partly differentiated tubular adenocarcinoma. As the third extrahepatic bile duct carcinoma cell line reported in world literature, TFK-1 has become a cornerstone model for biliary tract cancer (BTC) research, exhibiting epithelial-like morphology, a population doubling time of approximately 37 hours, and a modal chromosome number of 73. The cell line demonstrates positive expression of c-erbB-2 (HER2) and MUC1 antigen, while tumor markers including CEA, CA19-9, ST-439, and DUPAN-2 remain negative, making it particularly suitable for studies focused on HER2-targeted therapies and mucin biology in cholangiocarcinoma.

In xenograft applications, TFK-1 tumors engraft reliably in immunodeficient mouse strains such as BALB/c nude mice, typically via subcutaneous inoculation of 5x10⁶ cells. The resulting tumors faithfully recapitulate key histopathological features of human extrahepatic cholangiocarcinoma, including glandular architecture, desmoplastic stroma, and moderate differentiation status. This model has been extensively validated across multiple independent studies for evaluating chemotherapeutic agents (e.g., gemcitabine, cisplatin), targeted therapies (e.g., Src inhibitors, HER2 blockade), epigenetic modulators (e.g., sodium valproate, decitabine), and oncolytic virotherapies, consistently demonstrating predictive value for clinical translatability.

Figure 1. H&E staining in BDC cell line-derived xenograft (TFK-1) and ODX2 (#1045) Scale bar-200 mm. (Ogawa H, et al., 2025)

Cell Line Information: TFK-1

The TFK-1 cell line represents one of the most extensively characterized and widely utilized models for extrahepatic biliary tract carcinoma research. Below is a comprehensive summary of its biological and technical specifications:

Our Services

Alfa Cytology leverages decades of collective expertise in tumor model development to deliver TFK-1 xenograft systems that meet the highest standards of preclinical rigor. Our integrated service portfolio encompasses cell line authentication via STR profiling, pathogen screening, optimized engraftment protocols tailored to your compound class, real-time tumor monitoring via caliper and bioluminescence imaging, and comprehensive endpoint analysis including histopathology, immunohistochemistry, flow cytometry, and pharmacokinetic/pharmacodynamic correlation---ensuring every study generates actionable, decision-driving data for your biliary tract cancer pipeline.

Workflow of TFK-1 Xenograft Model Construction

Alfa Cytology follows a standardized, quality-controlled workflow for TFK-1 xenograft model construction, ensuring reproducible tumor growth kinetics, consistent histopathological fidelity, and optimal therapeutic windows for compound evaluation. Each step is executed under GLP-compliant documentation and rigorous quality assurance protocols.

1. Cell Line Authentication & Quality Control: TFK-1 cells are authenticated via short tandem repeat (STR) profiling against the reference database, confirmed for mycoplasma negativity by PCR, and verified for passage number consistency (typically passages 5--20 post-resuscitation) to maintain genomic stability and engraftment reliability.
2. Cell Expansion & Harvest Preparation: Cells are expanded in RPMI-1640 medium supplemented with 10% FBS under standard culture conditions (37 degrees C, 5% CO₂). At 70--80% confluence, cells are harvested using trypsin-EDTA, washed with PBS, and resuspended in serum-free medium or Matrigel/PBS mixture (1:1) at a concentration of 5x10⁶ cells per 100--200 uL injection volume.
3. Mouse Strain Selection & Conditioning: Immunodeficient mice (BALB/c nude or NOD-SCID) aged 6--8 weeks are acclimatized for 7 days under SPF conditions. Body weight and health status are recorded daily. Randomization into treatment cohorts is performed prior to tumor cell inoculation to minimize bias.
4. Subcutaneous Tumor Cell Inoculation: The TFK-1 cell suspension (5x10⁶ cells in 100--200 uL) is injected subcutaneously into the right flank of each mouse using a 25-gauge needle. Tumor formation is monitored by palpation every 2--3 days; palpable tumors typically appear within 7--14 days post-inoculation.
5. Tumor Monitoring & Randomization: Once tumors reach 50--100 mm³ (approximately 10--14 days post-implantation), mice are randomized into treatment and control groups (n=7--10 per arm). Tumor dimensions are measured twice weekly using digital calipers, and tumor volume is calculated via the formula: V = (length x width²) / 2.
6. Therapeutic Intervention & Dosing: Test compounds are administered according to the study protocol---via intraperitoneal, intravenous, or oral gavage routes---at predetermined dose levels and schedules. Vehicle-only controls receive equivalent volumes of the formulation buffer. Body weight and clinical signs are monitored daily throughout the treatment period.
7. Endpoint Assessment & Tissue Collection: At study termination (typically when control tumors reach 1,500--2,000 mm³ or per protocol-defined criteria), mice are humanely euthanized. Tumors are excised, weighed, and photographed. Tissues are allocated for formalin-fixed paraffin-embedded (FFPE) histopathology, snap-frozen for molecular analysis, or dissociated for flow cytometry and cell profiling.
8. Data Analysis & Reporting: Tumor growth inhibition (TGI) is calculated as [(V_control_final - V_control_initial) - (V_treated_final - V_treated_initial)] / (V_control_final - V_control_initial) x 100%. Statistical significance is determined by two-way ANOVA with Bonferroni post-hoc testing. A comprehensive study report including raw data, statistical analysis, representative images, and methodological details is delivered within 2--4 weeks of study completion.

Figure 2. TFK-1 xenograft model construction workflow.

Case Study-TFK-1 Xenograft Model Development

Alfa Cytology has successfully established and validated the TFK-1 xenograft model across multiple independent drug efficacy campaigns, encompassing diverse therapeutic modalities including small-molecule kinase inhibitors, epigenetic modulators, antibody-drug conjugates, and oncolytic viral vectors. In a representative study, TFK-1 tumors engrafted with 100% take rate in BALB/c nude mice, achieving consistent tumor volumes of 150--250 mm³ within 14 days post-implantation---providing an optimal therapeutic window for compound evaluation. Treatment with a panel of reference compounds demonstrated dose-dependent tumor growth inhibition (TGI) ranging from 35% to 78%, with corresponding reductions in Ki67 proliferation index and increases in apoptotic marker expression (cleaved caspase-3) as confirmed by immunohistochemistry. Pharmacokinetic correlation studies further established exposure-efficacy relationships, enabling robust PK/PD modeling. Detailed datasets, including individual animal tumor growth curves, body weight trajectories, histopathological scoring, and biomarker quantification, are available upon formal inquiry and protected under client confidentiality agreements.

Why Choose Alfa Cytology?

Partnering with Alfa Cytology for your TFK-1 biliary tract cancer xenograft studies ensures access to a scientifically rigorous, operationally flexible, and client-centric preclinical service platform designed to de-risk your therapeutic development decisions.

• Proven Track Record: TFK-1 xenograft models validated across multiple independent studies with consistent engraftment rates, reproducible tumor growth kinetics, and predictive translatability for diverse compound classes.
• Integrated Service Architecture: From cell line sourcing and authentication to in vivo pharmacology, biomarker analysis, and regulatory-compliant reporting, all under one contract research partner.
• Customizable Study Design: Flexible dosing regimens, combination therapy arms, biomarker-driven endpoints, and orthogonal model systems (e.g., patient-derived xenografts, orthotopic models) to match your specific scientific questions.
• Real-Time Data Transparency: Secure client portal access to study progress, raw data uploads, and interim analysis reports, enabling agile decision-making throughout the project lifecycle.
• Regulatory-Ready Documentation: GLP-compliant protocols, IACUC-approved animal welfare standards, and audit-ready data packages that support IND-enabling and publication submissions.
• Dedicated Scientific Support: Each project is assigned a PhD-level study director with deep expertise in hepatobiliary oncology, ensuring strategic input from study design through data interpretation.

Contact Us

Ready to advance your biliary tract cancer therapeutic pipeline with a validated TFK-1 xenograft model? Contact us today to discuss your project requirements, receive a customized study proposal, and explore how Alfa Cytology's preclinical expertise can accelerate your path from discovery to development. Our scientific team is standing by to reach out and guide you through every stage of your TFK-1 xenograft study---from initial consultation to final data delivery.

For research use only. Not intended for any clinical use.